Common menu bar links

---

Table 1: Rhabdomyolysis, myopathy and increased CPK reactions associated with statins as reported to the CADRMP from date marketed in Canada to Aug. 24, 2001*

---

Drug and year marketed in Canada; no. of reports

Reaction†	Atorvastatin 1997	Cerivastatin 1998	Fluvastatin 1994	Lovastatin 1988	Pravastatin 1990	Simvastatin 1990
Rhabdomyolysis	10	54	-	12	3	7
Myopathy‡	32	8	5	24	17	34
CPK increased with   myopathy‡	16	11	1	6	4	6
CPK increased without   myopathy‡	5	6	-	4	6	5
Total no. of  reports received	231	121	43	182	123	170

---

Note:

CPK = creatine phosphokinase, CADRMP = Canadian Adverse Drug Reaction Monitoring Program.

* These data cannot be used to determine the incidence of adverse drug reactions because neither patient exposure nor the amount of time the drug was on the market has been taken into consideration. See caveat at the end of the newsletter.

Each report may contain more than 1 of these reactions; however, reports were only included in the most significant category.

‡ Myopathy may include muscle symptoms such as myositis, myalgia, muscle ache, muscle weakness, muscle cramp, muscle discomfort.